iX Biopharma Ltd. · SGX:42C
iX Biopharma — Shareholder Meeting (2020)
21 slides from iX Biopharma's shareholder meeting presentation, 2020
Slide 1: iX Biopharma Ltd Corporate Update, AGM 2020
iX Biopharma Ltd Corporate Update, AGM 2020
Slide 2: Disclaimer
DISCLAIMER The information in this presentation has not been independently verified. iX Biopharma Ltd (the “Company”) makes no representation or warranty (whether express or implied) whatsoever in this presentation, and no reliance should be placed on the information or opinions contained in this pr
Slide 3: Agenda
AGENDA 1) Company Overview 2) Gaining Access to New Markets 3) COVID-19 Impact 4) Summary
Slide 4: Company Overview
COMPANY OVERVIEW
Slide 5: Company Profile
Company Profile Who we are ➢ Specialty pharmaceutical company with expertise in drug delivery systems Competitive Advantage ➢ Developed a patented sublingual wafer technology, WaferiX ➢ Drug formulation > Clinical studies > Regulatory > Manufacturing > Sales Fully Integrated Model ➢ Competitive adva
Slide 6: GMP Manufacturing Facility
GMP Manufacturing Facility ➢ Situated in Croydon, Melbourne (40mins drive from central business district) ➢ Total land area - 12,000m² ➢ Built to Pharma grade - 3,173m² ✓ TGA licensed GMP facility ✓ Manufacturing ✓ Clean rooms - 23 ✓ Lab testing ✓ Warehousing ✓ Administration ✓ Carpark – 74 lots ➢ U
Slide 7: iX Syrinx Pty Ltd
iX Syrinx Pty Ltd 1 State of the art manufacturing equipment ➢ Extensive suite of state of the art equipment including tablets, capsules, freeze drying & packaging machines Freezer Dryers Blister Packing Machine 2 Manufacturing capabilities ➢ Patented sublingual wafers manufactured using proprietary
Slide 8: WaferiX, A Proprietary Drug Delivery Technology
, A Proprietary Drug Delivery Technology ➢ WaferiX is a novel, patented, non-invasive & fast-dissolving sublingual wafer that delivers various active compounds safely via the oral mucous membrane located under the tongue ➢ Proven & validated platform technology - Australian TGA approval received for
Slide 9: Diversified products & markets
Diversified products & markets Nutraceuticals Wafesil ➢ Condition specific products, perceptible change ➢ Male erectile dysfunction ➢ Focused on beauty & lifestyle ➢ AU, CN, EU markets ➢ CN, AU markets ➢ Direct supply & out-licensing ➢ Direct supply & out-licensing models models WaferiX ➢ Patented s
Slide 10: WaferiX to drive 3 growth engines
WaferiX to drive 3 growth engines 1) Wafermine Pharmaceuticals 2) Wafesil, Supergenerics 1) Medicinal Cannabis 2) Wellness 1) LumeniX Nutraceuticals 2) NAD+ Competitive advantages of sublingual wafer; ✓ fast disintegration ✓rapid onset of therapeutic action ✓easy to use ✓ ~ 1 million wafers sold acr
Slide 11: Wafermine
Wafermine ➢ Potent non-opioid painkiller, safer than opioids (no respiratory depression) ➢ Can be used as a substitute or adjunct to opioids ➢ When approved, it will be the World’s first ketamine drug approved for pain management ➢ Well-positioned for out-licensing: ✓ Following a successful End-of-P
Slide 12: Gaining Access to New Markets
GAINING ACCESS TO NEW MARKETS
Slide 13: Wafesil & Silcap – China, Australia, SG
Wafesil & Silcap – China, Australia, SG ➢ China Pharmaceutical Market ✓ Wafesil out-licensed to Yiling Pharmaceutical Ltd for China market in April 2020 ➢ Australia telemedicine ✓ Commenced sale of Wafesil & Silcap through telemedicine ✓ Patients consult with & obtain prescriptions from doctors digi
Slide 14: Entity – China
Entity – China ➢ Entity has opened flagship stores on Tmall Global & JD Worldwide ✓ Tmall & JD together command 85% of the cross border e-commerce market ➢ 2 leading products well-received by Chinese consumers; 1) LumeniX, sublingual glutathione wafers, for skin beauty and fairness 2) RestoriX, supp
Slide 15: Medicinal Cannabis – Australia
Medicinal Cannabis – Australia ➢ Commenced supply of Xativa, broad spectrum CBD (cannabidiol), in Australia ✓ Formulated using WaferiX sublingual delivery technology ✓ World’s first freeze-dried medicinal cannabis sublingual wafer ✓ Doctors prescribe Xativa for anxiety & pain ✓ Xativa was featured b
Slide 16: COVID-19 Impact
COVID-19 IMPACT
Slide 17: Expansion of Production Capacity
Expansion of Production Capacity ➢ COVID-19 has impacted all industries and changed the way we conduct business ➢ Supply chains have been disrupted ➢ Our wafer production capacity expansion plan has been impacted ✓ Expansion planned in early 2020, now delayed due to border closures ✓ Installation en
Slide 18: Impact on Deal Making
Impact on Deal Making ➢ Travel Restriction ➢ Strong interest in WaferiX technology for superior drug delivery from US, China, EU, UK ➢ Face to face meetings, the essential element of deal making, is not possible with border closures ✓ Especially in China where “Guan Xi” is paramount ➢ Video conferen
Slide 19: Summary
SUMMARY
Slide 20: Summary
Summary ➢ Balance Sheet strengthened with S$10.2M placement in Sep 2020 3 Growth Engines Market Access Wafermine Wafermine EOP2 meeting Wafermine (Phase 3 Ready) (Phase 3 Ready) with FDA ✓ Commenced out-licensing process Global Acute pain market ~US$7B ✓ Global phenomenon, consumer driven Cannabis ✓
Slide 21: Thank You
} > —e S e) a Le